Moberg Pharma AB (publ) (MOB) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone and thank you for joining the Moberg Pharma Q3 Earnings Call. My name is Becky and I will be your operator today. During the presentation, you can register a question by pressing star followed by one on your keypad. If you change your mind, please press star followed by two. I will now hand over to your host, CEO of Moberg Pharma, Anna Young, to begin. Please go ahead. Thank you and good afternoon everyone. Thank you for joining our Q3 earnings call today. I'm Anna Jung, CEO of Mobut Pharma, and I also have our VP of Finance, Mark Beveridge, with me today. We're happy to present our Q3 report that you can find on our webpage. There you can also find a PowerPoint presentation that I'll base this call upon. And this call will be recorded and uploaded to our webpage. In today's call, I'll be providing an overview of our performance this quarter, discussing key developments in our business, and highlighting important strategic milestones. Starting with the positive developments, I'm proud to report that Teclara continues to lead the market in Sweden. The launch has exceeded our expectations, making a strong and successful market entry that has established our presence effectively. Year-to-date, we captured 30% of the market share by value and 25% by units in pharmacy sales to end consumers. Teclara became first available in stores in February this year. with the bulk of initial resets appearing on the shelves from March. Looking at the period from the first full month of sales, in April, to the end of this quarter, Petlara reached a market share of 37% in value and 31% in units in pharmacy sales to consumers. For Q2 specifically, those figures amounted to 34% by value and 78% by units. Our distribution network has expanded. with its Terclara now available ...